| HST |
Report |
FFO/share |
IN-LINE |
pred ~$0.620 vs. cons $0.615 |
MEDIUM |
| HST |
Report |
Comparable RevPAR growth |
BEAT |
pred ~4.6% vs. cons 4.19% |
MEDIUM |
| HST |
Report |
Adjusted EBITDAre |
BEAT |
pred ~$525M vs. cons $517.7M |
MEDIUM |
| HST |
Guide |
FY26 Adjusted FFO/share |
LOWER |
guide ~$2.10–$2.16 vs. cons $2.152 |
MEDIUM |
| HST |
Guide |
FY26 Comparable RevPAR growth |
BETTER |
guide ~3.0%–4.5% vs. cons 2.51% |
MEDIUM |
| HST |
Guide |
FY26 Adjusted EBITDAre |
UNCHANGED |
guide ~$1.785B–$1.835B vs. cons $1.814B |
MEDIUM |
| HST |
Guide |
3Q26 RevPAR commentary |
BETTER |
guide ~2% low-single-digit growth vs. cons 1.81% |
LOW |
| HST |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| HST |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guide implies lower 4Q FFO |
LOW |